Dyadic International Inc (DYAI) stock
DYAINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.32−0.00 (-1.25%)
Close on Nov 17, 2026Market cap $11.51MP/E –Yield –
Dyadic International r&d expenses
Research and development expenses are spending on new products and technology.
Dyadic International's R&D Expenses for the twelve months ending Sep 30, 2026 was $1.70M, down 24.3% year over year. For fiscal 2025 it was $2.15M, up 5.4% from the year before. The highest annual figure on record is $8.39M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.15M | +5.4% |
| FY2024 | Dec 31, 2024 | $2.04M | -38.0% |
| FY2023 | Dec 31, 2023 | $3.30M | -26.7% |
| FY2022 | Dec 31, 2022 | $4.50M | -46.4% |
| FY2021 | Dec 31, 2021 | $8.39M | +117.0% |
| FY2020 | Dec 31, 2020 | $3.87M | +25.3% |
| FY2019 | Dec 31, 2019 | $3.09M | +46.9% |
| FY2018 | Dec 31, 2018 | $2.10M | +19.0% |
| FY2017 | Dec 31, 2017 | $1.77M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $429.95K | -24.8% |
| Q2 FY2026 | Jun 30, 2026 | $332.62K | -47.2% |
| Q1 FY2026 | Mar 31, 2026 | $476.07K | -3.8% |
| Q4 FY2025 | Dec 31, 2025 | $458.44K | -16.0% |
| Q3 FY2025 | Sep 30, 2025 | $571.87K | +24.3% |
| Q2 FY2025 | Jun 30, 2025 | $629.38K | +22.1% |
| Q1 FY2025 | Mar 31, 2025 | $494.98K | -5.3% |
| Q4 FY2024 | Dec 31, 2024 | $545.66K | -36.0% |
| Q3 FY2024 | Sep 30, 2024 | $460.24K | -35.8% |
| Q2 FY2024 | Jun 30, 2024 | $515.63K | -43.8% |
| Q1 FY2024 | Mar 31, 2024 | $522.72K | -35.5% |
| Q4 FY2023 | Dec 31, 2023 | $852.80K | +46.0% |
| Q3 FY2023 | Sep 30, 2023 | $716.35K | -3.7% |
| Q2 FY2023 | Jun 30, 2023 | $917.55K | -49.9% |
| Q1 FY2023 | Mar 31, 2023 | $810.57K | -39.6% |
| Q4 FY2022 | Dec 31, 2022 | $584.12K | -76.4% |
| Q3 FY2022 | Sep 30, 2022 | $743.59K | -60.9% |
| Q2 FY2022 | Jun 30, 2022 | $1.83M | -17.1% |
| Q1 FY2022 | Mar 31, 2022 | $1.34M | -99.9% |
| Q4 FY2021 | Dec 31, 2021 | $2.47M | +144.8% |
| Q3 FY2021 | Sep 30, 2021 | $1.90M | +92.8% |
| Q2 FY2021 | Jun 30, 2021 | $2.21M | +97.9% |
| Q1 FY2021 | Mar 31, 2021 | $1.81B | +239239.6% |
| Q4 FY2020 | Dec 31, 2020 | $1.01M | +37.4% |
| Q3 FY2020 | Sep 30, 2020 | $986.05K | +17.2% |
| Q2 FY2020 | Jun 30, 2020 | $1.12M | +36.4% |
| Q1 FY2020 | Mar 31, 2020 | $755.45K | +9.1% |
| Q4 FY2019 | Dec 31, 2019 | $735.64K | +64.6% |
| Q3 FY2019 | Sep 30, 2019 | $841.34K | +76.5% |
| Q2 FY2019 | Jun 30, 2019 | $818.24K | +36.1% |
| Q1 FY2019 | Mar 31, 2019 | $692.37K | +20.0% |
| Q4 FY2018 | Dec 31, 2018 | $446.91K | – |
| Q3 FY2018 | Sep 30, 2018 | $476.63K | – |
| Q2 FY2018 | Jun 30, 2018 | $601.20K | – |
| Q1 FY2018 | Mar 31, 2018 | $576.88K | – |
See a number that looks wrong?